Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-04-17
1999-11-23
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
424 4, A61K 31557
Patent
active
059901683
ABSTRACT:
Embodiments of the invention include formulations for the treatment of (AT) ataxia telangiectasia patient and asymptomatic AT heterozygous carriers. The subject formulations comprise one or more different prostaglandins and a pharmaceutically acceptable carrier. Preferably the prostaglandins are group E prostaglandins, prostaglandin E2 being particularly preferred. Other embodiments of the invention include methods of treating AT patients and AT carriers. These methods comprise the steps of administering an effective amount of a prostaglandin containing composition of the invention. Other embodiments of the invention include methods of treating AT patients and carriers with radiotherapy. The methods comprise the steps of administering and effective amount of a prostaglandin containing formulations of the invention and subsequently irradiating the subject with an amount of radiation sufficient to achieve the desired therapeutic effect. Other embodiments of the invention include methods of radioimaging AT patients and AT carriers. The methods comprise the steps of administering an effective amount of a prostaglandin containing formulation of the invention and subsequently irradiating the subject with an amount of radiation to produce a diagnostic image of interest.
REFERENCES:
Askew, et al., 1989, "Molecular Recognition with Convergent Functional Groups. Synthethic and Structural Studies with a Model Receptor for Nucleic Acid Components", J. Am. Chem. Soc. 111:108-1090.
Aurias and Dutrillaux, 1986, "A possible new type of chromosome rearrangement: telomere-centromere translocation (tct) followed by double duplication", Hum. Genet. 72: 25-26.
Aurias and Dutrillaux, 1986, "Probable involvement of immunoglobulin superfamily genes in most recurrent chromosomal rearrangements from ataxia telangiectasia", Hum. Genet. 72:210-214.
Bar et al., 1978, "Extreme Insulin Resistance in Ataxia Telangiectasia", New Eng. J. Med. 298:1164-1171.
Beamish and Lavin, 1994, "Radiosensitivity in ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay", Int. J. Radiat. Biol. 65:175-184.
Bigbee et al., 1989, "Evidence for an Elevated Frequency of In Vivo Somatic Cell Mutations in Ataxia Telangiectasia", Am. J. Hum. Genet. 44:402-408.
Corey et al., 1969, Stereo-Controlled Synthesis of Prostaglandins F.sub.2.alpha. and E.sub.2 (dl), J. Am. Chem. Soc. 91:5675-5677.
Croce et al., 1985, "Gene for .alpha.-Chain of Human T-Cell Receptor: Location on Chromosome 14 Region Involved in T-Cell Neoplasms", Science 227:1044-1047.
Ford and Easton, 1995, "The genetics of breast of ovarian cancer", Br. J. Cancer 72:805-812.
Gatti et al., 1991, "Ataxia-Telangiectasia: An Interdisciplinary Approach to Pathogenesis", Medicine 70:99-117.
Hartwell and Kastan, 1994, "Cell Cycle Control and Cancer", Science 266:1821-1828.
Heather et al., 1973, "Total Synthesis of Prostaglandins. V. A Synthesis of (.times. )-Prostaglandin E.sub.2 Via a Totally Asymmetric Process", Tetrahedron Letters 25:2313-2316.
Henderson et al., 1985, "Diagnosis of Ataxia-Telangiectasia by T-Lymphocyte Cloning Assay", Lancet 11:1242.
Hernandez et al., 1993, "A family showing no evidence of linkage between the ataxia telangiectasia gene and chromosome 11 q22-23", J. Med. Genet. 30:135-140.
Houghten et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery", Nature 354:84-86.
Hynes, 1992, "Integrins: Versatility, Modulation, and Signaling in Cell Adhesion", Cell 69:11-25.
Jaspers et al., 1988, "Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients", Cytogenet. Cell Genet. 49:259-263.
Kastan et al., 1992, "A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia", Cell 71:587-597.
Kastan et al., 1991, "Participation of p53 Protein in the Cellular Response to DNA Damage", Cancer Res. 51:6304-6311.
Khanna & Lavin, 1993, "Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells", Oncogene 8:3307-3312.
Kuerbitz et al., 1992, "Wild-type p53 is a cell cycle checkpoint determinant following irradiation", Pro. Natl. Acad. Sci. USA 89:7491-7495.
Kuhnlein and Paterson, 1990, "Increased uracil-DNA glycosylase, AP-DNA binding protein and deoxyribonuclease activities in tumor and SV40-transformed cell lines of huma origin", Carcinogenesis 11:117-121.
Lam, et al., 1991, "A new type of synthetic peptide library for identifying ligand-binding activity", Nature 354:82-84.
Lewis and Dean, 1989, "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation", Proc. R. Soc. Lond. 236:125-140.
Lewis and Dean, 1989, "Automated site-directed drug design: the formation of molecular templates in primary structure generation", Proc. R. Soc. Lond. 236:141-162.
McKinaly and Rossmann, 1989, "Rational Design of Antiviral Agents", Annu. Rev. Pharmacol. Toxiciol. 29: 111-122.
Mohamed et al., 1987, "A Defect in DNA Topoisomerase II Activity in Ataxia-Telangiectasia Cells", Biochem. Biophys Res. Commun. 149:233-238.
Pippard et al., 1988, "Cancer in Homozygotes and Heterozygotes of Ataxia-Telangiectasia and Xeroderma Pigmentosum in Britain", Cancer Res. 48:2929-2932.
Ripka, Jun. 16, 1988, "Computers picture the perfect drug", New Scientist 54-57.
Rosin et al., 1989, "Heterogeneity of chromosomal breakage levels in epithelial tissue of ataxia-telangiectasia homozygotes and heterozygotes", Hum. Genet. 83:133-138.
Rouvinen et al., 1988, "Computer-Aided Drug Design", Acta Pharmaceutical Fennica 97:159-166.
Russo et al., 1989, "Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient", Proc. Natl. Acad. Sci. 86:602-606.
Savitsky et al., 1995, "A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase", Science 268:1749-1753.
Saxon et al., 1979, "Helper and Suppressor T-Lymphocyte Leukemia in Ataxia Telangiectasia", New Eng. J. Med. 300:700-704.
Sedgwick and Boder (1991) in Handbook of Clinical Neurology: Hereditary Neuropathies and Spinocellular Atrophies vol. 16(60) (P.J. Ninken et al., edu.), pp. 347-423, Elsevier Science, Amsterdam.
Shaham and Becker, 1981, "The Ataxia Telangiectasia Clastogenic Factor is a Low Molecular Weight Peptide", Hum. Genet. 58:422-424.
Shiloh et al., 1989, "G.sub.2 chromosomal radiosensitivity in families with ataxia-telangiectasia", Hum. Genet. 84:15-18.
Songyang et al., 1993, "SH2 Domains Recognize Specific Phosphopeptide Sequences", Cell 72:767-778.
Swift et al., 1991, "Incidence of Cancer in 161 Families Affected by Ataxia-Telangiectasia", New Eng. J. Med. 325:1831-1836.
Swift et al., 1987, "Breast and Other Cancers in Families with Ataxia-Telangiectasia", New Eng. J. Med. 316:1289-1294.
Weeks et al., 1991, "Assessment of Chronic .gamma. Radiosensitivity as an in Vitro Assay for Heterozygote Identification of Ataxia-Telangiectasia", Radiat. Res. 128:90-99.
Woods and Taylor, 1992, "Ataxia Telangiectasia in the British Isles: The Clinical and Laboratory Features of 70 Affected Individuals", Quart. J. Med. 82:169-179.
Wooster et al., 1993, "Absence of linkage to the ataxia telangiectasia locus in familial breast cancer", Hum. Genet. 92:91-94.
Zakian, 1995, "ATM-Related Genes: What do They Tell Us about Functions of the Human Gene?", Cell 82:685-687.
Mirzayans Razmik
Paterson Malcolm C.
Alberta Cancer Board
Gerstl Robert
LandOfFree
Methods and compositions for the treatment of ataxia telangiecta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of ataxia telangiecta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of ataxia telangiecta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1222584